Skip to content

NURIX THERAPEUTICS, INC.

NRIX

CIK 0001549595

← back to feed
Revenue (TTM)
$76.66M
+54.0% YoY Q1 Apr 2026
Net Income (TTM)
−$273.41M
−36.6% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$3.01
−5.9% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-384.9%
Q1 Apr 2026
Net Margin
-356.7%
Q1 Apr 2026
Free Cash Flow (TTM)
−$233.1M
Q1 Apr 2026
Cash
$71.2M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
103.41M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings